pimagedine has been researched along with Diabetes Mellitus in 47 studies
pimagedine: diamine oxidase & nitric oxide synthase inhibitor; an advanced glycosylation end product inhibitor; used in the treatment of diabetic complications; structure
aminoguanidine : A one-carbon compound whose unique structure renders it capable of acting as a derivative of hydrazine, guanidine or formamide.
Diabetes Mellitus: A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "N(epsilon)-(Carboxymethyl)lysine (CML), a major product of oxidative modification of glycated proteins, has been suggested to represent a general marker of oxidative stress and long-term damage to proteins in aging, atherosclerosis, and diabetes." | 7.69 | Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging. ( Nerlich, AG; Schleicher, ED; Wagner, E, 1997) |
| "N(epsilon)-(Carboxymethyl)lysine (CML), a major product of oxidative modification of glycated proteins, has been suggested to represent a general marker of oxidative stress and long-term damage to proteins in aging, atherosclerosis, and diabetes." | 3.69 | Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging. ( Nerlich, AG; Schleicher, ED; Wagner, E, 1997) |
| "Hyperglycemia is considered a key causal factor in the development of diabetic vascular complications and can mediate its adverse effects through multiple pathways." | 2.41 | Glycation as the glucose link to diabetic complications. ( Gugliucci, A, 2000) |
| "Glyoxal was also observed to significantly inhibit EC proliferation." | 1.36 | Hyperglycemic oxoaldehyde, glyoxal, causes barrier dysfunction, cytoskeletal alterations, and inhibition of angiogenesis in vascular endothelial cells: aminoguanidine protection. ( Butler, ES; Eubank, TD; Kotha, SR; Kuppusamy, ML; Kuppusamy, P; Marsh, CB; Parinandi, NL; Roy, S; Sherwani, SI; Sliman, SM; Stern, DM, 2010) |
| " These observations may be of importance in proposals for the long term administration of AG in diabetes." | 1.29 | Aminoguanidine: a drug proposed for prophylaxis in diabetes inhibits catalase and generates hydrogen peroxide in vitro. ( Ou, P; Wolff, SP, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.13) | 18.7374 |
| 1990's | 19 (40.43) | 18.2507 |
| 2000's | 24 (51.06) | 29.6817 |
| 2010's | 3 (6.38) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Okada, Y | 1 |
| Ishimaru, A | 1 |
| Suzuki, R | 1 |
| Okuyama, T | 1 |
| Wang, S | 1 |
| Li, B | 1 |
| Li, C | 1 |
| Cui, W | 1 |
| Miao, L | 1 |
| Sliman, SM | 1 |
| Eubank, TD | 1 |
| Kotha, SR | 1 |
| Kuppusamy, ML | 1 |
| Sherwani, SI | 1 |
| Butler, ES | 1 |
| Kuppusamy, P | 1 |
| Roy, S | 1 |
| Marsh, CB | 1 |
| Stern, DM | 1 |
| Parinandi, NL | 1 |
| Országhová, Z | 1 |
| Liptáková, A | 1 |
| Muchová, J | 1 |
| Ulicná, O | 1 |
| Vancová, O | 1 |
| Sivonová, M | 1 |
| Bozek, P | 1 |
| Cársky, J | 1 |
| Duracková, Z | 1 |
| Sun, Z | 1 |
| Chen, J | 1 |
| Ma, J | 1 |
| Jiang, Y | 1 |
| Wang, M | 1 |
| Ren, G | 1 |
| Chen, F | 1 |
| Kawakami, M | 1 |
| Kuroki, M | 1 |
| Aronson, D | 1 |
| Gardiner, TA | 1 |
| Anderson, HR | 1 |
| Stitt, AW | 1 |
| Vasan, S | 1 |
| Foiles, P | 1 |
| Founds, H | 1 |
| Chen, AS | 1 |
| Taguchi, T | 1 |
| Aoyama, S | 1 |
| Sugiura, M | 1 |
| Haruna, M | 1 |
| Wang, MW | 1 |
| Miwa, I | 1 |
| Menè, P | 1 |
| Festuccia, F | 1 |
| Pugliese, F | 1 |
| Jakus, V | 1 |
| Rietbrock, N | 1 |
| Ishikawa, N | 1 |
| Miyata, T | 2 |
| Kurokawa, K | 1 |
| Ge, K | 1 |
| Lu, SL | 1 |
| Qing, C | 1 |
| Pennathur, S | 1 |
| Ido, Y | 1 |
| Heller, JI | 1 |
| Byun, J | 1 |
| Danda, R | 1 |
| Pergola, P | 1 |
| Williamson, JR | 1 |
| Heinecke, JW | 1 |
| Zhong, W | 1 |
| Wang, LL | 1 |
| Cui, H | 1 |
| Li, S | 1 |
| Yamamoto, M | 1 |
| Izuhara, Y | 1 |
| Machado, AP | 1 |
| Pinto, RS | 1 |
| Moysés, ZP | 1 |
| Nakandakare, ER | 1 |
| Quintão, EC | 1 |
| Passarelli, M | 1 |
| Rajasekar, P | 1 |
| Anuradha, CV | 1 |
| Kani, S | 1 |
| Nakayama, E | 1 |
| Yoda, A | 1 |
| Onishi, N | 1 |
| Sougawa, N | 1 |
| Hazaka, Y | 1 |
| Umeda, T | 1 |
| Takeda, K | 1 |
| Ichijo, H | 1 |
| Hamada, Y | 1 |
| Minami, Y | 1 |
| Bucala, R | 1 |
| Makita, Z | 1 |
| Vega, G | 1 |
| Grundy, S | 1 |
| Koschinsky, T | 1 |
| Cerami, A | 1 |
| Vlassara, H | 3 |
| Ou, P | 1 |
| Wolff, SP | 1 |
| Monnier, V | 1 |
| Wolffenbuttel, BH | 1 |
| Huijberts, MS | 1 |
| Booth, AA | 1 |
| Khalifah, RG | 2 |
| Hudson, BG | 2 |
| Friedman, EA | 2 |
| Skamarauskas, JT | 1 |
| McKay, AG | 1 |
| Hunt, JV | 1 |
| Schleicher, ED | 1 |
| Wagner, E | 1 |
| Nerlich, AG | 1 |
| Shimabukuro, M | 2 |
| Ohneda, M | 1 |
| Lee, Y | 1 |
| Unger, RH | 2 |
| Zhou, YT | 1 |
| Levi, M | 1 |
| Reihsner, R | 2 |
| Menzel, EJ | 2 |
| Baynes, JW | 2 |
| Ohta, M | 1 |
| Weiss, MF | 1 |
| Saxena, AK | 1 |
| Monnier, VM | 1 |
| Melling, M | 1 |
| Pfeiler, W | 1 |
| Zhang, J | 1 |
| Ren, S | 1 |
| Shen, GX | 1 |
| Gugliucci, A | 1 |
| Price, DL | 1 |
| Rhett, PM | 1 |
| Thorpe, SR | 1 |
| Bonnefont-Rousselot, D | 1 |
| Du, Y | 1 |
| Smith, MA | 1 |
| Miller, CM | 1 |
| Kern, TS | 1 |
| Brownlee, M | 3 |
| Kumari, K | 1 |
| Umar, S | 1 |
| Bansal, V | 1 |
| Sahib, MK | 1 |
21 reviews available for pimagedine and Diabetes Mellitus
| Article | Year |
|---|---|
Potential Renoprotective Agents through Inhibiting CTGF/CCN2 in Diabetic Nephropathy.
Topics: Animals; Anthocyanins; Antibodies, Monoclonal; Connective Tissue Growth Factor; Diabetes Mellitus; D | 2015 |
[Aminoguanidine and other AGE inhibitors].
Topics: Amides; Animals; Arteriosclerosis; Cardiovascular Diseases; Cataract; Clinical Trials as Topic; Diab | 2002 |
Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes.
Topics: Aging; Animals; Arteries; Collagen; Diabetes Mellitus; Diastole; Elasticity; Glycation End Products, | 2003 |
Therapeutic potential of breakers of advanced glycation end product-protein crosslinks.
Topics: Aging; Animals; Clinical Trials as Topic; Cross-Linking Reagents; Diabetes Mellitus; Diastole; Drug | 2003 |
Clinical potential of advanced glycation end-product inhibitors in diabetes mellitus.
Topics: Clinical Trials as Topic; Diabetes Mellitus; Enzyme Inhibitors; Glycation End Products, Advanced; Gu | 2003 |
Advanced glycation end-products and the progress of diabetic vascular complications.
Topics: Arteriosclerosis; Diabetes Complications; Diabetes Mellitus; Glycation End Products, Advanced; Glyco | 2004 |
[Carbonyl stress inhibitor towards new therapeutic interventions in diabetic nephropathy].
Topics: Amides; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihyp | 2004 |
[Aminoguanidine and impaired wound healing in diabetes].
Topics: Animals; Diabetes Mellitus; Diabetes Mellitus, Experimental; Guanidines; Humans; Nitric Oxide Syntha | 2004 |
[Targeted AGEes and AGEs cross-link in drug discovery: preventing and reversing arterial sclerosis in aging and diabetes].
Topics: Aging; Animals; Arteries; Arteriosclerosis; Blood Pressure; Diabetes Mellitus; Glycation End Product | 2005 |
[Non-enzymatic glycosylation of proteins. Complications of diabetes mellitus, aging and kidney failure].
Topics: Aging; Arginine; Blood Glucose; Diabetes Mellitus; Diabetic Neuropathies; Glycation End Products, Ad | 1993 |
Will pimagidine improve survival of diabetics on dialysis?
Topics: Arteriosclerosis; Diabetes Complications; Diabetes Mellitus; Glycation End Products, Advanced; Guani | 1996 |
Advanced glycation end-products and atherosclerosis.
Topics: Animals; Arteriosclerosis; Diabetes Mellitus; Endothelium, Vascular; Enzyme Inhibitors; Glycation En | 1996 |
Advanced glycosylated end products and hyperglycemia in the pathogenesis of diabetic complications.
Topics: Aldehyde Reductase; Animals; Clinical Trials as Topic; Diabetes Mellitus; Disease Models, Animal; En | 1999 |
Amadorins: novel post-Amadori inhibitors of advanced glycation reactions.
Topics: Diabetes Mellitus; Drug Design; Glycation End Products, Advanced; Guanidines; Pyridoxamine; Schiff B | 1999 |
[Current advances in the treatment of diabetes mellitus].
Topics: Aldehyde Reductase; Arteriosclerosis; Blood Glucose; Diabetes Mellitus; Enzyme Inhibitors; Guanidine | 1999 |
Glycation as the glucose link to diabetic complications.
Topics: Arteriosclerosis; Diabetes Complications; Diabetes Mellitus; Diabetic Angiopathies; Glycated Hemoglo | 2000 |
Intervening in atherogenesis: lessons from diabetes.
Topics: Arteriosclerosis; Cooking; Diabetes Mellitus; Diet, Atherogenic; Enzyme Inhibitors; Glucose; Glycati | 2000 |
[Antioxidant and anti-AGE therapeutics: evaluation and perspectives].
Topics: Antioxidants; Chromans; Diabetes Mellitus; Gliclazide; Glycation End Products, Advanced; Guanidines; | 2001 |
Glycation products and the pathogenesis of diabetic complications.
Topics: Animals; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetic Retino | 1992 |
Nonenzymatic glycosylation of macromolecules. Prospects of pharmacologic modulation.
Topics: Animals; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Glycosylation; G | 1992 |
Pharmacological modulation of the advanced glycosylation reaction.
Topics: Animals; Blood Proteins; Chemical Phenomena; Chemistry; Diabetes Complications; Diabetes Mellitus; G | 1989 |
1 trial available for pimagedine and Diabetes Mellitus
| Article | Year |
|---|---|
Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency.
Topics: Animals; Cholesterol; Diabetes Mellitus; Diabetic Nephropathies; Enzyme-Linked Immunosorbent Assay; | 1994 |
25 other studies available for pimagedine and Diabetes Mellitus
| Article | Year |
|---|---|
A new phloroglucinol derivative from the brown alga Eisenia bicyclis: potential for the effective treatment of diabetic complications.
Topics: alpha-Amylases; Diabetes Mellitus; Enzyme Inhibitors; Glycation End Products, Advanced; Japan; Molec | 2004 |
Hyperglycemic oxoaldehyde, glyoxal, causes barrier dysfunction, cytoskeletal alterations, and inhibition of angiogenesis in vascular endothelial cells: aminoguanidine protection.
Topics: Animals; Cattle; Cell Proliferation; Cells, Cultured; Cytoskeleton; Diabetes Mellitus; Endothelial C | 2010 |
Influence of pyridoxylidene aminoguanidine on biomarkers of the oxidative stress and selected metabolic parameters of rats with diabetes mellitus.
Topics: Aldehydes; Animals; Antioxidants; Biomarkers; Diabetes Mellitus; DNA Damage; Guanidines; Lipoprotein | 2009 |
Cynarin-rich sunflower (Helianthus annuus) sprouts possess both antiglycative and antioxidant activities.
Topics: Antioxidants; Cinnamates; Diabetes Mellitus; Glycation End Products, Advanced; Guanidines; Helianthu | 2012 |
Inhibition of advanced glycation end-products protects against retinal capillary basement membrane expansion during long-term diabetes.
Topics: Animals; Basement Membrane; Capillaries; Diabetes Mellitus; Diabetic Retinopathy; Enzyme-Linked Immu | 2003 |
Antioxidant activity of a Schiff base of pyridoxal and aminoguanidine.
Topics: Animals; Antioxidants; Ascorbic Acid; Aspartate Aminotransferases; Benzoates; Blood Glucose; Body We | 2003 |
Reactive carbonyls and polyunsaturated fatty acids produce a hydroxyl radical-like species: a potential pathway for oxidative damage of retinal proteins in diabetes.
Topics: Amino Acids; Animals; Antioxidants; Carbon; Cerebral Cortex; Chromatography, High Pressure Liquid; D | 2005 |
From molecular footprints of disease to new therapeutic interventions in diabetic nephropathy.
Topics: Animals; Antioxidants; Biomarkers; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetic Neph | 2005 |
Aminoguanidine and metformin prevent the reduced rate of HDL-mediated cell cholesterol efflux induced by formation of advanced glycation end products.
Topics: Albumins; Animals; Atherosclerosis; Cells, Cultured; Cholesterol, HDL; Diabetes Mellitus; Enzyme Inh | 2006 |
L-Carnitine inhibits protein glycation in vitro and in vivo: evidence for a role in diabetic management.
Topics: Animals; Blood Glucose; Carnitine; Diabetes Mellitus; Diaphragm; Dietary Carbohydrates; Fructosamine | 2007 |
Chk2 kinase is required for methylglyoxal-induced G2/M cell-cycle checkpoint arrest: implication of cell-cycle checkpoint regulation in diabetic oxidative stress signaling.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Acetylcysteine; Cell Line; Checkpoint Kinase 1; Checkpoint Kinase 2; De | 2007 |
Aminoguanidine: a drug proposed for prophylaxis in diabetes inhibits catalase and generates hydrogen peroxide in vitro.
Topics: Amitrole; Animals; Catalase; Copper; Diabetes Mellitus; Erythrocytes; Guanidines; Humans; Hydrogen P | 1993 |
Aminoguanidine, a potential drug for the treatment of diabetic complications.
Topics: Animals; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Guanidines; Hum | 1993 |
Thiamine pyrophosphate and pyridoxamine inhibit the formation of antigenic advanced glycation end-products: comparison with aminoguanidine.
Topics: Animals; Antigens; Cattle; Diabetes Complications; Diabetes Mellitus; Enzyme Inhibitors; Glycation E | 1996 |
Aminoguanidine and its pro-oxidant effects on an experimental model of protein glycation.
Topics: Chymotrypsin; Diabetes Mellitus; Endopeptidases; Glycated Serum Albumin; Glycation End Products, Adv | 1996 |
Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging.
Topics: Adult; Aged; Aging; Antibodies; Arteries; Arteriosclerosis; Biomarkers; Blood Proteins; Catalase; Ch | 1997 |
Role of nitric oxide in obesity-induced beta cell disease.
Topics: Animals; Blood Glucose; Cells, Cultured; Diabetes Mellitus; Diabetes Mellitus, Type 2; Fatty Acids, | 1997 |
Fatty acid-induced beta cell apoptosis: a link between obesity and diabetes.
Topics: Animals; Apoptosis; Cells, Cultured; Ceramides; Chromans; Coenzyme A Ligases; Diabetes Mellitus; Dia | 1998 |
Two-dimensional stress-relaxation behavior of human skin as influenced by non-enzymatic glycation and the inhibitory agent aminoguanidine.
Topics: Aged; Biomechanical Phenomena; Diabetes Mellitus; Elasticity; Enzyme Inhibitors; Glucose-6-Phosphate | 1998 |
Pharmacological modulation of AGEs: a unique role for redox-active metal ions.
Topics: Animals; Antioxidants; Chelating Agents; Diabetes Mellitus; Glycation End Products, Advanced; Guanid | 1999 |
Alterations of biochemical and two-dimensional biomechanical properties of human skin in diabetes mellitus as compared to effects of in vitro non-enzymatic glycation.
Topics: Aged; Aged, 80 and over; Biomechanical Phenomena; Cadaver; Case-Control Studies; Diabetes Mellitus; | 2000 |
Glycation amplifies lipoprotein(a)-induced alterations in the generation of fibrinolytic regulators from human vascular endothelial cells.
Topics: Biomarkers; Blotting, Northern; Cardiovascular Diseases; Cells, Cultured; Diabetes Complications; Di | 2000 |
Chelating activity of advanced glycation end-product inhibitors.
Topics: Amines; Antioxidants; Ascorbic Acid; Bromides; Chelating Agents; Copper; Diabetes Complications; Dia | 2001 |
Diabetes-induced nitrative stress in the retina, and correction by aminoguanidine.
Topics: Animals; Cattle; Cells, Cultured; Cyclic GMP; Diabetes Complications; Diabetes Mellitus; Diabetic Re | 2002 |
Monoaminoguanidine inhibits aldose reductase.
Topics: Aldehyde Reductase; Animals; Diabetes Mellitus; Drug Design; Guanidines; Kinetics; Lens, Crystalline | 1991 |